Administration & Agency Updates

Recent Administration & Agency Updates

COVID-19 Boosters Remain Safe, Continue to Offer High Levels of Protection Against Severe Disease Over Time and During Omicron and Delta Waves

On February 11, 2022, the Centers for Disease Control and Prevention (CDC) announced the data from two CDC reports indicate that COVID-19 vaccine booster shots continue to be safe and are highly effective against severe COVID-19 disease over time.   The data for the first report was from vaccine safety monitoring systems, v-safe, and the Vaccine Adverse Event Reporting System (VAERS). In this set of…

Indian Health Service Distributing Free N-95 Masks

To ramp up access to high-quality masks amid the spread of the Omicron variant, Indian Health Service (IHS)-operated facilities, Tribally-operated facilities, and Urban Indian Organizations have received N95 respirator masks from the IHS National Supply Service Center for free distribution to patients, health center staff, and other individuals within the community. Upon request, IHS will distribute the N-95 masks to health care facilities operated…

COVID-19 Vaccine for Children Six Months Through Four Years Old Coming Soon!

In the U.S. there are approximately 18 million children ages six months through four years old. These children are at risk of getting COVID-19, especially the Omicron Variant. Both Pfizer-BioNTech and Moderna vaccines are underway in clinical trials and data collection for children under five years old. The Emergency Use Authorization (EUA) application for the Pfizer-BioNTech vaccine for this age group has been submitted…

FDA Approved Moderna (Spikevax) COVID-19 Vaccine

On February 4, 2022, the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of the Moderna COVID-19 Vaccine in adults 18 and older.   The Moderna COVID-19 vaccine, now being marketed as Spikevax, received full U.S. Food and Drug Administration (FDA) approval on January 31, 2022, for people ages 18 years and over. The…

Ivermectin Products Do Not Prevent or Treat COVID-19

The U.S. Food and Drug Administration (FDA) has not authorized or approved the use of ivermectin to prevent or treat COVID-19 in humans or animals. The FDA approved ivermectin to treat infections in humans caused by some parasitic worms and head lice and skin conditions like rosacea. American Indians and Alaska Natives (AI/ANs) should be cautious about taking medication meant for animals as well as…

Expansion of Treatment for Outpatients with Mild-to-Moderate COVID-19

At a time when effective therapies against the Omicron and Delta variants are in high demand, the U.S. Food and Drug Administration (FDA) recently approved Veklury (Remdesivir) to treat non-hospitalized adult and adolescent patients at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for treating patients hospitalized…

Contact Us

To reach the NIHB COVID-19 Response Team, please contact [email protected].

For media inquiries, please contact Ned Johnson at [email protected].

© Copyright 2020, National Indian Health Board. All Rights Reserved. Website by DrawBridge Creative.

Privacy Policy

This website is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of financial assistance awards totaling $2,000,000, Tribal Capacity Building for COVID-19 Disease Control, and $4,000,000, Addressing COVID-19 Vaccine Confidence Through Tribal Health Departments, with 80 percent funded by CDC/HHS, and 20 percent funded by non-government source(s). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.